Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes

Fig. 2

Immunologic alterations in tumor-bearing mice treated with chemotherapy and/or anti-BTLA Ab. a The percentages of CD223 expression of CD4+ T lymphocytes in splenocytes of various therapeutic groups. The percentage of CD223+CD4+ T lymphocytes in splenocytes was highest in paclitaxel combined with anti-BTLA Ab 20 μg/mouse group (p = 0.001, Kruskal-Wallis test). (5 mice in each group) b The percentages of CD223 expression of CD8+ T lymphocytes in splenocytes of various therapeutic groups. The percentage of CD223+CD8+ T lymphocytes in splenocytes was also highest with paclitaxel combined with anti-BTLA Ab 20 μg/mouse (p = 0.001, Kruskal-Wallis test). (5 mice in each group) c The percentages of CD223 expression of CD4+ T lymphocytes in TACs of ascites of various therapeutic groups. The percentage of CD223+CD4+ T lymphocytes in TACs of ascites was highest with paclitaxel and anti-BTLA Ab 20 μg/mouse (p = 0.001, Kruskal-Wallis test). (5 mice in each group) d The percentages of CD223 expression of CD8+ T lymphocytes in TACs of ascites of various therapeutic groups. The percentage of CD223+CD8+ T lymphocytes in TACs of ascites was also highest with paclitaxel combined with anti-BTLA Ab 20 μg/mouse (p = 0.001, Kruskal-Wallis test). (5 mice in each group) e Tumoricidal activity of splenocytes of tumor-bearing mice receiving chemotherapy treated with/without anti-BTLA Ab in vitro. e1 Representative luminescence figures of the in vitro tumor killing abilities of splenocytes by the IVIS system. (5 mice in each group) e2 Quantification of luminescence of in vitro tumor killing abilities of splenocytes by the IVIS system. Compared with the luminescence of WF-3/Luc cells co-cultured with splenocytes without anti-BTLA Ab, less luminal activity was detected in WF-3/Luc cells co-cultured with splenocytes receiving in vitro anti-BTLA Ab (p = 0.021 for WF-3/Luc:splenocyte = 1:100; p = 0.027 for WF-3/Luc:splenocyte = 1:50; and p = 0.039 for WF-3/Luc:splenocyte = 1:10, Kruskal-Wallis test). The splenocytes treated with anti-BTLA Ab could generate higher tumor killing activities than those without anti-BTLA Ab. (5 mice in each group) f Bar figures of concentrations of various cytokines in ascites of various groups. Note: F1: IL-12; F2: TNF-α; F3: IFN-γ; F4: IL-6; F5: IL-10; and F6: TGF-β. The pro-inflammatory cytokines such as IL-12 (p = 0.002), TNF-α (p = 0.002), and IFN-γ (p = 0.001) were highest with the chemotherapy combined with anti-BTLA Ab 20 μg/mouse. The concentrations of ant-inflammatory cytokines such as IL-6 (p = 0.83), IL-10 (p = 0.85), and TGF-β (p = 0.84) did not show differences among the various groups (all statistical analyses by Kruskal-Wallis test). (5 mice in each group)

Back to article page